⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

Solengepras, A Novel GPR6-inhibitor, Shows Potential to Improve Sleep Disturbance in Parkinson’s Disease: Results from the ASCEND Phase Two Trial (P8-17.017)

Harini Sarva Aaron Ellenbogen Kelvin Chou Stuart Isaacson Rajesh Pahwa Shabbir Hussain Merchant Tim Sheehan Ulysses Diva Nicola Brice Michelle Charles Sagar Vaidya Xiao Xu Jordan Dubow Karl Kieburtz Robert Hauser

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the effects of solengepras on sleep quality and non-motor symptoms in early Parkinson’s disease.
Phase 2 clinical trial to assess solengepras effects.
Population consisted of individuals with early Parkinson’s disease.
Outcome measures focused on sleep disturbance and non-motor symptoms.
Solengepras led to significant improvement in sleep disturbance compared to placebo (exact metrics not specified).
Improvements in non-motor symptoms were also observed, indicating broad benefits for early Parkinson’s patients.

Implication

Shows solengepras improves sleep and non-motor symptoms in early Parkinson’s disease, suggesting potential therapeutic benefits.

Abstract

To determine the effect of solengepras on sleep and non-motor symptoms in a Phase 2 study in early Parkinson’s disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sarva et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f05632c https://doi.org/10.1212/wnl.0000000000213107

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Characteristics of OFF-time Improvement in a Phase Two Study for Parkinson’s Disease (PD) with Solengepras, a Novel GPR6-inhibitor (P8-17.006)Early-Phase Clinical Trial · 2026
2Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease2024 · 142 citations
3Enhancing sleep slow waves with auditory stimulation in people with Parkinson’s disease: a randomized proof-of-concept trialRCT · 2026
4<scp>AZP2006</scp> in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open‐Label Extension on Safety, Biomarkers, and Disease Progression2025 · 4 citations
5Home-based deep sleep modulation in Parkinson’s disease: extension study on long-term feasibility and sleep-related outcomesOriginal Research · 2026

More related papers

Enhancing sleep slow waves with auditory stimulation in people with Parkinson’s disease: a randomized proof-of-concept trial2026
Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson’s disease2026
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial2024

More from Neurology

Recanalization After Acute Cervical Artery DissectionTue,
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSDTue,